FSS PROJECTS
Below you will find a list of some of the projects we have worked on over the last 20 years.
HERA
The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>
EPoS
The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had...
NordICC
Learn how Frontier science scotland partnered with the University of Oslo for the nordicc study In collaboration with the University of Oslo, FSS held responsibility for trial data collection,...
FINESSE
Frontier Science has worked in partnership with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and in collaboration with Institut de Recherches Internationales...
ALEXANDRA
ALEXANDRA is a clinical trial partnership between Roche, the Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet (IJB) and Frontier Science. This is a phase 3,...
TOMORROW
Frontier Science collaborated with Janssen Actelion on the TOMORROW trial. The study assessed the efficacy, safety and pharmacokinetics of macitentan (Opsumit®) versus standard of care in children...
ALTTO & NEO-ALTTO
Frontier Science collaborated with the Breast International Group (BIG) on the ALTTO and Neo-ALTTO trials. These trials were built on the results from the successful HERA trial and aimed to study...
APHINITY
APHINITY is a large, randomised phase III, double-blind, placebo-controlled study that compares the efficacy and safety of chemotherapy plus trastuzumab and placebo with that of chemotherapy plus...
OlympiA
OlympiA is a randomized, double-blind, parallel group, placebo-controlled multi-center phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients...
NoTOPain
NoTOPain was a randomised, crossover, placebo controlled, double-blind, Phase II study of cetuximab in patients with treatment-refractory, non-malignant severe chronic neuropathic pain. Neuropathic...